CPL 207 280 CA
Alternative Names: CPL'280; CPL207-280; CPL207-280CA; CPL207280-51; GPR40 agonist - Celon PharmaLatest Information Update: 28 Mar 2024
Price :
$50 *
At a glance
- Originator Celon Pharma
- Class Analgesics; Antihyperglycaemics; Carboxylic acids; Obesity therapies; Phenyl ethers; Small molecules
- Mechanism of Action FFAR1 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- Preclinical Neuropathic pain
- No development reported Diabetic neuropathies; Obesity
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Diabetic-neuropathies(In volunteers) in Poland (PO)
- 02 Oct 2023 Preclinical trials in Neuropathic pain in Poland (PO) before October 2023
- 02 Oct 2023 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical trial in Neuropathic pain presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)